ALI et al./Turk J Chem
1H, J = 6.0 Hz, Ph–H), 7.16 (d, 1H,J =8.2 Hz, Ph–H), 7.45–7.98 (m, 8H, Ph–H), 7.39 (d, 1H, JPH = 512 Hz,
P–H), 8.06 (d, 1H, JPH = 406 Hz, P–H), 8.47 (s, 2H, C5 –Hpyrazole ), 9.80 (s, 2H, CH=Nexocyclic).31 P NMR
(DMSO-d6 , δ): 8.29 (pyrazole–P–pyrazole), 17.70 (NH–P–NH). m/z (relative intensity %): 462 (M–2, 0.2),
324 (100), 231 (18), 104 (16), 77 (70), 65 (24), 51 (24). Anal. Calcd. for C20 H18 N8 O2 P2 (464.36): C, 51.73;
H, 3.91; N, 24.13. Found: C, 51.45; H, 3.59; N, 23.72%.
13,33-Diphenyl-6,8-dihydro-5,6,8,9-tetraaza-2-phosphoryl-7-methoxyphosphoryl-1,3-(1,4)-
dipyrazolacyclodecaphan-4,9-diene (5b): Mp 232–234 ◦ C. IR (KBr, cm−1): 3429 (br, NH), 3055 (C–
Harom), 2992 (C–Haliph), 2353 (P–H), 1602 (C=Nexocyclic), 1534 (C=C), 1294, 1209 (2 P=O), 1053 (P–O–
C). 1 H NMR (DMSO-d6 , δ): 3.35 (s, 3H, OCH3), 5.24 (brs, 2H, NH exchangeable with D2 O), 6.52 (d, 1H,
J = 8.4 Hz, Ph–H), 7.02–7.20 (m, 3H, Ph–H), 7.40 (d, 1H, JPH = 513 Hz, P–H), 7.32–7.54 (m, 4H, Ph–H),
7.76 (d, 1H, J = 7.2 Hz, Ph–H), 8.02 (d, 1H, J = 7.2 Hz, Ph–H), 8.49 (s, 2H, C5 –Hpyrazole), 9.81 (s, 2H,
CH=Nexocyclic).m/z (relative intensity %): 494 (M+ , 3.3), 463 (3), 246 (41), 231 (15), 116 (12), 77 (100), 51
(32). Anal. Calcd. for C21 H20 N8 O3 P2 (494.38): C, 51.02; H, 4.08; N, 22.67. Found: C, 50.79; H, 3.69; N,
22.25%.
2.2. General procedure for macrocycles 8a, 8b and 9a, 9b
A hot ethanolic solution (10 mL) of bis(4-formyl-3-(4‘-biphenyl)-1H-pyrazol-1-yl) phosphine oxides (1b) (1.08
g, 2 mmol) was mixed with a hot ethanolic solution of appropriate diamine (2 mmol in 10 mL), namely
hydrazine hydrate (6a), 1,2-ethylenediamine (6b), 1,2-phenylenediamine (7a), and 1,4-phenylenediamine (7b)
in the presence of 2 drops of glacial acetic acid. The solution mixture was heated under reflux for 4 h. The
resulting solids were filtered off and crystallized from dimethylformamide to give the corresponding macrocycles
8a, 8b and 9a, 9b, respectively, as yellow crystals with yields of 48%–85%.
13,33,83,103-Tetris(4‘-biphenyl)-5,6,12,13-tetraaza-2,9-diphosphoryl-1,3,8,10(1,4)-tetrapy-
razolacyclotetradecaphane-4,6,11,13-tetraene (8a): Mp 232–235 ◦ C. IR (KBr, cm−1): 3057 (C–Harom),
2363 (P–H), 1614 (C=Nexocyclic), 1597 (C=Nendocyclic), 1533 (C=C), 1209 (P=O). 1 H NMR (DMSO-d6 ,
δ): 7.56 (d, 1H, JPH = 590 Hz, P–H), 7.67 (d, 1H, JPH = 612 Hz, P–H), 6.50–7.99 (m, 36H, Ar–H), 8.46
(s, 2H, C5 –Hpyrazole ), 8.65 (s, 2H, C5 –Hpyrazole), 9.78 (s, 4H, CH=Nexocyclic).m/z (relative intensity %):
1073 (M–4H, 0.1), 882 (0.2), 734 (0.3), 452 (0.5), 307 (3), 293 (11), 167 (24), 149 (100), 127 (13), 96 (11), 57
(35). Anal. Calcd. for C64 H46 N12 O2 P2 (1077.07): C, 71.37; H, 4.30; N, 15.61. Found: C, 71.63; H, 4.44; N,
15.23%.
13,33,103,123-Tetris(4‘-biphenyl)-5,8,14,17-tetraaza-2,11-diphosphoryl-1,3,10,12(1,4)-tet-
rapyrazolacyclooctadecaphane-4,8,13,17-tetraene (8b): Mp 218–220 ◦ C. IR (KBr, cm−1): 3053 (C–
H
arom), 2880, 2844 (C–Haliph), 2362 (P–H), 1633 (C=Nexocyclic), 1595 (C=Nendocyclic), 1539 (C=C), 1214
(P=O). 1 H NMR (DMSO-d6 , δ): 3.79 (t, 8H, 2 CH2 CH2), 7.59 (d, 1H, JPH = 619 Hz, P–H), 7.69 (d, 1H,
JPH = 633 Hz, P–H), 6.51–8.28 (m, 36H, Ar–H), 8.49 (s, 2H, C5 –Hpyrazole), 8.87 (s, 2H, C5 –Hpyrazole), 9.80
(s, 2H, CH=Nexocyclic), 9.99 (s, 2H, CH=Nexocyclic). Anal. Calcd. for C68 H54 N12 O2 P2 (1133.18): C, 72.07;
H, 4.80; N, 14.83. Found: C, 71.72; H, 4.59; N, 14.42%.
13,33,93,113-Tetris(4‘-biphenyl)-6,14(1,2)-dibenzene-5,7,13,15-tetraaza-2,10-diphosph-oryl-
1,3,9,11(1,4)-tetrapyrazolacyclohexadecaphane-4,7,12,15-tetraene (9a): Mp 299–300 ◦ C. IR (KBr,
cm−1): 3057 (C–Harom), 2361 (br, P–H), 1615 (C=Nexocyclic), 1595 (C=Nendocyclic), 1533 (C=C), 1209
162